Quality-of-life outcomes in long-term survivors of advanced prostate cancer.
Quality-of-life outcomes in long-term survivors of advanced prostate cancer.
复制标题
晚期前列腺癌长期幸存者的生活质量结果。
DOI：
--
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
Thanh
中科院分区：
文献类型：
--
作者：
M. Litwin;A. I. Shpall;Frederick J. Dorey;Thanh
作者评估了接受手术或药物去势治疗的男性的健康相关生活质量（HRQOL）的时间进展，以及是否任何一种治疗都会对患者的生活质量产生更大的影响。作者在一项纵向观察性研究中，使用两种自我管理的经验证工具（兰德36项健康调查和UCLA前列腺癌指数）评估了一般和前列腺靶向HRQOL，该研究纳入了63例新诊断为转移性前列腺癌并接受双侧睾丸切除术或亮丙瑞林和氟西汀联合雄激素阻断治疗的男性。患者在基线时以及治疗开始后3个月和6个月时通过邮件完成两项HRQOL工具。在前12个月内，所有男性的14个HRQOL领域中有10个领域都有显著改善。这些包括所有八个一般HRQOL领域和解决肠功能的疾病特异性领域。作者在比较接受睾丸切除术与联合雄激素阻断的男性时，发现在任何一般或前列腺靶向HRQOL领域均无差异。可以告知转移性前列腺癌患者，无论他们选择药物或手术去势，一般和前列腺特异性HRQOL将是相似的，并且在治疗的最初几个月内，健康状况可能保持稳定或改善。医生必须让患者意识到他们可以期待晚期前列腺癌的生活质量和数量，并积极参与他们的治疗决策。
The authors evaluate the temporal progression of health-related quality of life (HRQOL) in men treated hormonally with surgical or medical castration, as well as to see if either treatment would be associated with a greater impact on patients' quality of life. The authors assessed general and prostate-targeted HRQOL with two self-administered, validated instruments (the RAND 36-Item Health Survey and the UCLA Prostate Cancer Index) in a longitudinal, observational study of 63 men newly diagnosed with metastatic prostate cancer and treated with bilateral orchiectomy or combined androgen blockade with leuprolide and flutamide. Patients completed the two HRQOL instruments by mail at baseline and at 3- and 6-month intervals after initiation of treatment. Significant improvements were demonstrated in 10 of 14 HRQOL domains for all men during the first 12 months. These include all eight of the general HRQOL domains and the disease-specific domains that address bowel function. The authors identified no differences in any of the general or prostate-targeted HRQOL domains when comparing men who underwent orchiectomy versus combined androgen blockade. Patients with metastatic prostate cancer can be informed that general and prostate-specific HRQOL will be similar, regardless of whether they choose medical or surgical castration, and that health status will likely remain stable or improve during the initial months of treatment. Physicians must make patients aware of both the quantity and quality of life they can expect with advanced prostate cancer, and must actively involve them in their treatment decisions.